Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADCY1 | Q08828 | 14/20 | 0.76 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.62 |
| ▸ | TSHR | P16473 | 3/20 | 0.62 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.62 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | MLNR | O43193 | 1/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | GMNN | O75496 | 1/20 | 0.61 |
| ▸ | BLM | P54132 | 1/20 | 0.61 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10764005 | 0.99 | ADCY1 (0.75) | ADCY1MAPK1CYP3A4TSHRNR1I2 | |
| SCHEMBL10763687 | 0.99 | ADCY1 (0.75) | ADCY1MAPK1CYP3A4TSHRNR1I2 | |
| Hydrochloric Acid SCHEMBL10766599 | 0.98 | ADCY1 (0.74) | ADCY1MAPK1CYP3A4TSHRNR1I2 | |
| SCHEMBL2231230 | 0.93 | ADCY1 (0.77) | ADCY1MAPK1CYP3A4TSHRNR1I2 | |
| SCHEMBL10763274 | 0.93 | ADCY1 (0.68) | ADCY1MAPK1CYP3A4TSHRNR1I2 | |
| Hydrochloric Acid SCHEMBL10766407 | 0.92 | ADCY1 (0.67) | ADCY1MAPK1CYP3A4TSHRNR1I2 | |
| Hydrochloric Acid SCHEMBL10696571 | 0.91 | ADCY1 (0.75) | ADCY1MAPK1CYP3A4TSHRNR1I2 | |
| Hydrochloric Acid SCHEMBL10763195 | 0.91 | ADCY1 (0.66) | ADCY1MAPK1CYP3A4TSHRNR1I2 | |
| SCHEMBL10762163 | 0.91 | ADCY1 (0.76) | ADCY1MAPK1CYP3A4TSHRNR1I2 | |
| Hydrochloric Acid SCHEMBL10764536 | 0.90 | ADCY1 (0.75) | ADCY1MAPK1CYP3A4TSHRNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140128399-A1 | METHODS AND COMPOSITIONS FOR TREATING URINARY TRACT INFECTIONS USING AGENTS THAT MIMIC OR ELEVATE CYCLIC AMP | DUKE UNIVERSITY (US) | 2014-05-08 | — | — | US | disclosed |
| US-5268471-A | Removing 1,9-O-isopropylidene protecting group | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-12-07 | — | — | US | disclosed |
| EP-0468444-A1 | Process for the preparation of 6-acyl, 7-acyl and 6,7-diacyl analogues of forskolin and intermediates thereof | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-01-29 | — | — | EP | disclosed |
| EP-0217372-A2 | Polyoxygenated labdane derivatives, process for their preparation and their use as medicaments | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128399-A1 | METHODS AND COMPOSITIONS FOR TREATING URINARY TRACT INFECTIONS USING AGENTS THAT MIMIC OR ELEVATE CYCLIC AMP | PDE7A, PDE8A, PDE8B | ADCY1 37/4885MAPK1 2510/4885CYP3A4 1974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.